Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
NCT07187479
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Kidney Disease (Stages 4 and 5)
- Kidney Disease
- Type 2 Diabetes
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Well Cell Global
- Last updated on ClinicalTrials.gov
- August 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- Arizona Kidney Disease and Hypertension Center · Phoenix, AZ
- Innovative Diabetic Center · Scottsdale, AZ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.